Ozempic’s Canadian Patent: A Critical Oversight with Huge Consequences
Novo Nordisk’s semaglutide-based drugs—Ozempic and Wegovy—have dominated Canada’s diabetes and obesity treatment market. In 2024, Ozempic ranked as the best-selling drug in the country, with retail sales around CAD 2.5 billion MarketWatchBenefits and Pensions Monitor. However, a seemingly minor administrative misstep changed everything.
In 2019, Novo Nordisk failed to pay a CAD 250 maintenance fee for its Canadian semaglutide patent—and when given a chance to reinstate it (with an additional late charge, totaling CAD 450), the company didn’t respond. That lapse caused the patent to irreversibly expire MarketWatch. Some analyses suggest this might not have been negligence but a calculated decision, as the company may have anticipated data exclusivity until January 2026 AInvestPatent Lawyer Magazine.
Despite this, data protection through regulatory exclusivity remains in place until January 2026, which still shields semaglutide from generics for a few more months MarketWatchBenefits and Pensions MonitorPatent Lawyer Magazine.
The Competitive Race Begins: Generic Players Poised for Entry
1. Sandoz
Sandoz has filed for approval with Health Canada and stands ready to launch generic semaglutide as soon as early 2026 Benefits and Pensions MonitorLabiotech.eu. As one of the world’s largest generics producers, Sandoz projects 60–70% price cuts, potentially offering medication at just CAD 40–50 per month Financial Times.
2. Biocon
India’s Biocon is pursuing an aggressive timeline, aiming to file for approval by September 2025 and launch in late 2026 or early 2027 in Canada Business StandardReuters. This effort includes generic versions of both Ozempic and Wegovy going through Health Canada and clinical trials.
3. Hims & Hers
Hims & Hers, a US-based telehealth company, is entering the Canadian market in 2026, offering generic semaglutide through its digital platform and personalized care services CNBCFierce HealthcareCP24. Their strategy emphasizes affordability and scale—coupled with telehealth support to make semaglutide treatment more accessible Benefits and Pensions MonitorFierce Healthcare.
4. Apotex & Others
Apotex and Hikma have also submitted generic semaglutide applications. Experts observe a flood of submissions from multiple firms, ready to capitalize post-2026 Patent Lawyer MagazineAInvest.
5. Dr. Reddy’s, Cipla, Eris Lifesciences
Other global players like Dr. Reddy’s, Cipla, Lupin, and Sun Pharma are preparing filings in Canada Benefits and Pensions Monitor. Meanwhile, Eris Lifesciences announced its intention to capture a major share of the emerging generic semaglutide market, likely launching early next year The Economic Times.
Opening the Door to Cost Savings and Greater Access
With multiple generics entering post-2026, pricing pressures are expected to dramatically reduce costs. Canada’s pan‑Canadian Pharmaceutical Alliance typically lowers prices to 35% of the branded version once four manufacturers compete. Given Ozempic’s current monthly list price of around CAD 223, generics could start at under CAD 78—and potentially even lower with more competition Benefits and Pensions Monitor+1.
Multiple analyses forecast price drops of 50–80% once generics hit Canadian pharmacies Labiotech.euFinancial TimesBenefits and Pensions Monitor.
Moreover, according to Grand View Research, semaglutide’s Canadian market value—estimated at USD 1.18 billion in 2024—is projected to rise to USD 4.03 billion by 2035 Benefits and Pensions Monitor.
Challenges and Strategic Barriers Facing Generics
1. Pen-Device Patents & Formulation Protection
While the core semaglutide compound is unprotected, Novo Nordisk still holds patents related to injection pen devices, formulations, and dosage regimens—some extending into the early 2030s Patent Lawyer Magazine. Creating compliant delivery systems will be a challenge for generic manufacturers.
2. Patent Linkage & NOC Regulations
Patent linkage in Canada typically protects brand-name drugs via the Notice of Compliance system, but the semaglutide patents aren’t listed on the Patent Register. As a result, some usual delays may not apply—but generics still must navigate remaining patents and regulatory hurdles Patent Lawyer Magazine.
3. Cross-Border Demand
Cheaper generics in Canada could spark demand from U.S. consumers. Florida already has federal approval to import some Canadian drugs, and similar programs may follow Financial TimesPatent Lawyer Magazine. This could strain Canadian supply, prompting export restrictions to ensure local access Financial Times.
Novo Nordisk’s Strategic Response
Novo defended its patent lapse as a “natural part of the pharmaceutical lifecycle,” pushing forward with new molecules, combinations, and formulations Financial Times. One such effort is Amycretin, a new weekly GLP‑1 agonist in Phase 3 trials, which could help them regain footing in the weight‑loss and diabetes markets AInvest.
Still, with core semaglutide exclusivity ending, Novo’s market dominance in Canada is at risk—reinforcing the urgency of launching the next-generation therapeutics.
Conclusion: A Canadian Turning Point in GLP‑1 Access
Canada is poised to become the first major Western market to have generics for semaglutide—due to a rare patent lapse and the imminent end of regulatory exclusivity WikipediaBarron’s. Starting January 2026, multiple companies—notably Sandoz, Biocon, Hims & Hers, Apotex, and others—are racing to launch affordable generics.
This shift could drive massive reductions in cost, broaden access to life-changing treatments, and set a precedent for other markets. However, challenges remain—particularly in pen-device innovation, regulatory barriers, and supply dynamics. Meanwhile, Novo Nordisk is recalibrating by pushing new therapeutic entrants like Amycretin.
The generics wave in Canada will not only reshape national healthcare—but potentially influence global pricing and access for semaglutide-based therapies.